Showing 5201-5210 of 9475 results for "".
- Dermatological Agents, NSAIDs Are Leading Prescription Cost Drivers in New 28-State WCRI Drug Trends Studyhttps://practicaldermatology.com/news/dermatological-agents-nsaids-are-leading-prescription-cost-drivers-in-new-28-state-wcri-drug-trends-study/2460809/In most states, dermatological agents accounted for about 20 percent of total prescription payments in the first quarter of 2020 (2020Q1), according to a
- Indoor Tanning Linked to Anxiety, Depressionhttps://practicaldermatology.com/news/indoor-tanning-linked-to-anxiety-depression/2460808/Indoor tanning early in life is associated with risk of anxiety and depression later in life, according to new research in the Journal of the American Academy of Dermatology. Excluding women wi
- Abbvie’s JAK1 Inhibitor Measures Up in Two Phase 3 Studies of ADhttps://practicaldermatology.com/news/abbvies-jak1-inhibitor-measures-up-in-two-phase-3-studies-of-ad/2460806/Upadacitinib yields rapid and significant improvements in patients with moderate to severe atopic dermatitis, according to results from two phase 3 clinical trials published online in The Lancet. Patients who received upadacitinib showed reductions in all clinical disease meas
- Curcumin Nanoparticles May Be Viable Adjuvant for Sunscreenhttps://practicaldermatology.com/news/curcumin-nanoparticles-may-be-viable-adjuvant-for-sunscreen/2460803/Curcumin may be a viable photoprotective adjuvant when delivered through nanoparticles, according to research published by a collaborative team from the George Washington University (GW) School of Medicine and Health Sciences (SMHS) Department of Dermatology and Albert Einstein College of Medicin
- It's a RAP: Allergan Set to Acquire Solitonhttps://practicaldermatology.com/news/deal-time-allergan-set-to-acquire-soliton/2460801/Allergan Aesthetics is set to acquire Soliton and Resonic, its Rapid Acoustic Pulse device. Resonic recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite. The ac
- HydraFacial and Vesper Healthcare Announce Closing of Business Combination, Combined Company Now Known as The Beauty Health Companyhttps://practicaldermatology.com/news/hydrafacial-and-vesper-healthcare-announce-close-business-combination-combined-company-now-known-as-the-beauty-health-company/2460800/It's officially official: Vesper Healthcare and The HydraFacial Company closed their previously announced business combination. The combined company will be known as The Beauty Health Company. The business combination was approved by Vesper Healthcare’s st
- Arcutis to Present New Data for Roflumilast in PsO at EADVhttps://practicaldermatology.com/news/arcutis-to-present-new-data-for-roflumilast-in-pso-at-eadv/2460798/New data from the DERMIS-1 and DERMIS-2 pivotal phase 3 studies evaluating roflumilast cream (ARQ-151) show that the investigational once daily, topical PDE4 inhibitor for psoriasis achieved the primary efficacy endpoint of IGA success at week eight for chronic plaque psoriasis. Data are being pr
- Mederma Survey: America's Got Skin Insecuritieshttps://practicaldermatology.com/news/mederma-survey-skin-insecurities-have-major-impact-on-mental-health/2460797/One-third of Americans would not use their smart phone for a year if it meant they could have picture-perfect skin, according to a new survey from Mederma. That’s not all they would do for clear skin either, many would cancel Netflix for life eat only oatmeal for a year, giv
- FDA Accepts Amgen's sNDA for Otezla in Mild-to-Moderate PsOhttps://practicaldermatology.com/news/fda-accepts-amgens-snda-for-otezla-in-mild-to-moderate-pso/2460796/FDA has accepted for review the supplemental New Drug Application (sNDA) for Amgen's Otezla® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA has set a PDUFA action date of
- CorEvitas Enrolls 15,000 Patients in its Psoriasis and AD Registrieshttps://practicaldermatology.com/news/corevitas-enrolls-15000-patients-in-its-psoriasis-and-ad-registries/2460795/CorEvitas has enrolled more than 15,000 patients with immune-mediated skin diseases in the CorEvitas registries for moderate to severe psoriasis and atopic dermatitis (AD). This milestone was achieved by building on the company's real-world evidence program and dermatolog